ASH 2022 | Advances in the management of R/R Hodgkin lymphoma
Catherine Diefenbach, MD, NYU Langone, New York, NY, outlines how the addition of novel agents has changed the treatment paradigm of relapsed/refractory (R/R) Hodgkin lymphoma over the last ten years. She highlights the addition of brentuximab vedotin and the subsequent development of immune checkpoint inhibitors (ICIs), adding that data on combinations of these agents could further maximize the benefit for patients over the next few years. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy, Research Funding; Celgene: Consultancy; FATE Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; Genmab: Consultancy; Gilead: Current equity holder in publicly-traded company; IMAB: Consultancy; Incyte: Research Funding; Kite: Consultancy; MEI Pharma: Research Funding; Merck: Consultancy, Research Funding; MorphoSys: Consultancy, Research Funding; Seattle Genetics: Research Funding.
